Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.
Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M. Hayashi M, et al. Among authors: ohnishi m. Circulation. 2003 May 27;107(20):2559-65. doi: 10.1161/01.CIR.0000068340.96506.0F. Epub 2003 May 5. Circulation. 2003. PMID: 12732605 Clinical Trial.
Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine.
Ohbayashi Y, Tsutamoto T, Sakaguchi T, Tanaka T, Kanamori T, Yokohama H, Sichiri G, Hukai D, Okabayashi T, Ozawa T, Ishii C, Tsutsui T, Ohno K, Ohnishi M, Wada A. Ohbayashi Y, et al. Among authors: ohnishi m. J Cardiovasc Pharmacol. 2003 Dec;42 Suppl 1:S71-4. doi: 10.1097/00005344-200312001-00016. J Cardiovasc Pharmacol. 2003. PMID: 14871033 Clinical Trial.
Endogenous bradykinin suppresses myocardial fibrosis through the cardiac-generated endothelin system under chronic angiotensin-converting enzyme inhibition in heart failure.
Fujii M, Wada A, Ohnishi M, Tsutamoto T, Matsumoto T, Yamamoto T, Takayama T, Dohke T, Isono T, Eguchi Y, Horie M. Fujii M, et al. Among authors: ohnishi m. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S346-9. doi: 10.1097/01.fjc.0000166265.09550.7c. J Cardiovasc Pharmacol. 2004. PMID: 15838317
1,201 results